Nextgen Pharmaceutical And Formulations Profile
Key Indicators
- Authorised Capital ₹ 0.90 M
- Paid Up Capital ₹ 0.30 M
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -26.51%
- Profit Growth -85.73%
- Ebitda 104.82%
- Net Worth 0.70%
- Total Assets -37.20%
About Nextgen Pharmaceutical And Formulations
Nextgen Pharmaceutical And Formulations Private Limited (NPAFPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 March 2016 (Eight years and 11 months 6 days old ). Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.90 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Rajesh Verma, Vikrant Mansana, and Meenakshi Shrimali serve as directors at the Company.
Company Details
-
Location
Indore, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230MP2016PTC035508
-
Company No.
035508
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Mar 2016
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Nextgen Pharmaceutical And Formulations?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Verma
|
Director | 09-Mar-2016 | Current |
|
Vikrant Mansana
|
Director | 22-Mar-2024 | Current |
|
Meenakshi Shrimali
|
Director | 22-Mar-2024 | Current |
Financial Performance of Nextgen Pharmaceutical And Formulations.
Nextgen Pharmaceutical And Formulations Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 26.51% decrease. The company also saw a substantial fall in profitability, with a 85.73% decrease in profit. The company's net worth moved up by a moderate rise of 0.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nextgen Pharmaceutical And Formulations?
In 2020, Nextgen Pharmaceutical And Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nextgen Pharmaceutical And Formulations?
Unlock and access historical data on people associated with Nextgen Pharmaceutical And Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nextgen Pharmaceutical And Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nextgen Pharmaceutical And Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
